Searches for Sculptra under the eyes run at about 1,300 a month in the US, with the temples adding a few hundred more (clickstream estimates, October 2026). Both areas sit outside the product's US label, and both appear by name in its safety sections. This page reads that label and the published studies as of 17 October 2026. It reports what is on record; it does not suggest anyone have the procedure, which is a decision for a licensed clinician.
What the label covers, and what it says about the eye
Sculptra is poly-L-lactic acid, approved by FDA under PMA P030050 — first in 2004 for HIV-associated facial fat loss, in 2009 for nasolabial folds and other facial wrinkles, and on 25 April 2023 (supplement S039) for fine lines and wrinkles in the cheek region. The labeling approved with that supplement lists three indications. None is the under-eye area or the temple. How the product works and its main trials are on our Sculptra page.
The warnings section speaks to the eye directly. Read on 17 October 2026, it says:
- "Sculptra injection in the periorbital area has not been studied. An increased risk of papules and nodules has been reported in published literature after injections in the periorbital area."
- Superficial injection "may be associated with increased local adverse events such as nodules and papules", with "special care" asked in patients with thin skin.
The post-marketing section, which summarises voluntary reports and published literature worldwide, adds three statements that concern this area:
- "Visual disturbances including blindness have been reported following injection of Sculptra into the temple area, periorbital areas, and/or cheek."
- Nodules occurring "in difficult anatomical regions (e.g. lower eyelid)", or persisting after other treatment, "required surgical excision".
- "Of the few granuloma cases that required hospitalization, these were associated with infraorbital use or injection in the lip vermilion."
That is the manufacturer's own labeling, not a critic's reading of it. The general side-effect record for the product is on our page about Sculptra's side effects.
Why the under-eye area is different
The lower eyelid has the thinnest dermis on the face: one ultrasound study cited on our page about polynucleotides under the eyes measured it at about 0.53 mm, against roughly 1.2 mm at the temple. Poly-L-lactic acid works by provoking a tissue response around particles, and the label's own warnings associate shallow placement and thin skin with papules and nodules. A lump that would be invisible under a thick cheek can show through an eyelid. That is the mechanism behind the label's caution, and it is why the case literature on this product clusters there.
What the under-eye studies report
A PubMed search for poly-L-lactic acid or Sculptra combined with periorbital, tear-trough, infraorbital, under-eye or lower-eyelid terms returned 32 records on 17 October 2026. Read by type, they are mostly reviews, technique papers and harm reports; the outcome studies are small:
| Study | Design | People | What it reported |
|---|---|---|---|
| Firsowicz, Kamrani, Goldman 2025 (PMID 40864851) | Retrospective chart review + survey, double-diluted PLLA below the orbicularis retaining ligament | 28 (19 answered the survey) | Mean physician improvement score 2.62 from photographs; satisfaction 3.37 of 5; bruising 21%, swelling 16%, one palpable nodule |
| Montes, Rohrich and colleagues 2025 (PMID 40627579) | Case series, Sculptra at the lower lid–midface transition | not stated in the abstract | Improvement in projection, pigmentation and texture described; "no unanticipated adverse events"; no control group. A separate 2025 report describes lower-lid tightening after treating the cheeks only (PMID 40911744) |
| Stewart 2007 (PMID 17667102) | Case report | 1 | Visible under-eye granulomas; non-surgical treatments failed; surgical excision |
| Roberts and Arthurs 2012 (PMID 21862947) | Case report | 1 | Blindness and eye-muscle paralysis on one side immediately after periorbital PLLA, from embolic orbital infarction |
| Fuller and Bradley 2015, JAMA Ophthalmology (PMID 26043419) | Case report | 1 | Facial ulcers and restricted eye movement from a delayed periorbital granuloma |
No randomized trial of poly-L-lactic acid under the eyes was found. The largest outcome report is retrospective, scores improvement from photographs, and recorded satisfaction from the two-thirds of patients who replied — a design that cannot measure how often uncommon harms occur.
The temples: one randomized trial
The temples have the stronger evidence. A 2026 randomized, evaluator-blinded, multicentre trial in China enrolled 174 people with moderate to severe temple hollowing and assigned them 2:1 to two or three sessions of a poly-L-lactic acid filler or to no treatment for six months (Chang 2026, PMID 41637104). At month 6, 96.5% of the treated group had improved by at least one grade on a temple-hollowing scale, against 0% of the untreated group, and the paper reports no treatment-related adverse events through 12 months. Its abstract describes "a PLLA facial filler" without naming Sculptra, and the comparison is with no treatment rather than with a hyaluronic-acid filler. A 2025 Brazilian consensus and a 2025 systematic review of temple fillers also cover the area.
The temple matters for safety for a different reason from the eyelid: its vessels connect to the circulation of the eye. A 2026 systematic review of visual loss after biostimulators counted two confirmed published cases with poly-L-lactic acid — one after periorbital/nasal injection and one after temple injection — against at least 11 with calcium hydroxylapatite (Young 2026, PMID 41263987). Two published cases is a floor, not a rate; the label's post-market wording covers reports that never became papers.
What is not established
How often nodules, granulomas or vision problems follow Sculptra under the eyes; whether any benefit there lasts; how it compares with hyaluronic-acid fillers, which can be dissolved, or with polynucleotide injections; and whether the temple trial's product behaves like Sculptra. How long the product lasts where it is labelled is covered in how long Sculptra lasts, and the other off-label body sites in our page on Sculptra on the neck, chest and hands. Anyone weighing this should put the label's periorbital statement in front of a licensed clinician.
Sources
Opened 17 October 2026: FDA PMA database entry for P030050/S039 (decision 25 April 2023) and the Sculptra labeling and patient guide filed with it (indications, warnings, post-marketing surveillance); PubMed records 40864851, 40627579, 40911744, 41637104, 41263987, 21862947, 26043419 and 17667102; the PubMed searches for poly-L-lactic acid with periorbital terms (32 records) and with temple terms (15 records); a check for retracted records in poly-L-lactic acid filler research (none of the papers cited here). Corrections go to the contact page.